|
Re: Revenue Canada
|
1
|
Resverlogix Corp.
|
Nov 15, 2019 08:17AM
|
|
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
|
1
|
Resverlogix Corp.
|
Jul 08, 2019 04:42PM
|
|
Re: Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
|
1
|
Resverlogix Corp.
|
Apr 27, 2021 03:32PM
|
|
Re: Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
|
1
|
Resverlogix Corp.
|
Apr 18, 2019 09:00AM
|
|
Re: Resverlogix warrants to be delisted June 21
|
2
|
Resverlogix Corp.
|
Jun 14, 2021 03:36PM
|
|
Re: Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
|
2
|
Resverlogix Corp.
|
Aug 14, 2019 10:26AM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
1
|
Resverlogix Corp.
|
Dec 02, 2019 10:08AM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
1
|
Resverlogix Corp.
|
Dec 02, 2019 11:21AM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
3
|
Resverlogix Corp.
|
Dec 02, 2019 01:49PM
|
|
Re: Resverlogix Secures One-Year Extension of Maturity Date of Debenture
|
1
|
Resverlogix Corp.
|
Jul 22, 2020 11:58AM
|
|
Re: Resverlogix Secures One-Year Extension of Maturity Date of Debenture
|
1
|
Resverlogix Corp.
|
Jul 22, 2020 12:05PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
1
|
Resverlogix Corp.
|
Nov 02, 2020 09:39AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
3
|
Resverlogix Corp.
|
Jun 22, 2020 10:56AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
|
Resverlogix Corp.
|
Jun 22, 2020 10:15PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
8
|
Resverlogix Corp.
|
Jun 22, 2020 10:43AM
|
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
5
|
Resverlogix Corp.
|
Oct 04, 2023 09:03AM
|
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
3
|
Resverlogix Corp.
|
Oct 04, 2023 11:41AM
|
|
Re: Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
|
2
|
Resverlogix Corp.
|
Aug 23, 2022 06:44AM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
4
|
Resverlogix Corp.
|
May 12, 2019 07:04AM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
2
|
Resverlogix Corp.
|
May 11, 2019 09:48AM
|
